RBM22

Across TCGA pan-cancer cohorts, RBM22 mass-spec protein is linked to patient survival in 5 of 34 cancer types, making it a survival-associated RBM22 data layer compared with 26 for mass-spec protein and 4 for mutation status.

The strongest signal is observed in head and neck squamous cell carcinoma (HNSC), where higher RBM22 mass-spec protein is associated with worse overall survival. In most high-consensus cancer types, elevated RBM22 expression acts as an unfavorable survival marker, although some lineages such as LUAD and PDAC show a favorable association.

HNSC, LUAD, and CCRCC are the cancer types where RBM22 mass-spec protein most reproducibly stratifies survival.

mass-spec protein survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
HNSC	OS	Median	All	0.770	0.912	.004	42	view →
LUAD	OS	Tertile	All	0.913	0.559	.008	14	view →
CCRCC	OS	Median	III,IV	0.485	1.000	.036	6	view →
PDAC	DFS	Tertile	All	0.835	0.698	.015	5	view →
GBM	OS	Quartile	All	0.536	0.293	.047	1	view →

Pink = unfavorable, green = favorable. Showing the 5 strongest of 5 lineages.

RBM22–HNSC (OS)

Open the HNSC breakdown →